Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
Lisata Therapeutics announced that Kuva Labs has commenced a tender offer to acquire all outstanding shares of Lisata common stock at $4.00 per share in cash, accompanied by a contingent value right (CVR) that offers up to $3.00 per share for achieving clinical and regulatory milestones related to their drug candidate, certepetide. The Lisata Board…